| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA874: Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma |
|
Medicine details |
|
| Medicine name | polatuzumab vedotin (Polivy®) |
| Formulation | 30 mg, 140 mg powder for solution for infusion |
| Reference number | 4561 |
| Indication | In combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) is indicated for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma |
| Company | Roche Products Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 07/04/2022 |
| NICE guidance | TA874: Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma |